

Име и презиме		Марина Костић	
Звање		Ванредни професор	
Назив институције у којој наставник ради са пуним радним временом и од када		Факултет медицинских наука, Универзитет у Крагујевцу	2008.
Ужа научна односно уметничка област		Фармакологија и токсикологија	
Академска каријера			
	Година		Област
Избор у звање	2018.	Факултет медицинских наука, Универзитет у Крагујевцу	Фармакологија и токсикологија
Докторат	2011.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Специјализација			
Магистратура			
Диплома	2006.	Медицински факултет, Универзитет у Крагујевцу	Медицина
Репрезентативне референце			
1.	Jović Z, Janković SM, Ružić Zečević D, Milovanović D, Stefanović S, Folić M, Milovanović J, Kostić M. Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis. <i>Eur J Drug Metab Pharmacokinet</i> . 2018; doi: 10.1007/s13318-018-0513-7.		
2.	Milosavljević MN, Janković SM, Pejić AV, Milovanović JR, Opančina VD, Kostić MJ. Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: meta-analysis. <i>Vojnosanit Pregl</i> . 2018;75(9):884-96.		
3.	Janković SM, Tešić D, Anđelković J, Kostić M. Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review. <i>Expert Rev Pharmacoecon Outcomes Res</i> 2018; 18(5):461-474.		
4.	Jankovic SM, Dajic M, Jacovic S, Markovic S, Papic T, Petrusic T, Radojkovic M, Rankovic A, Tanaskovic M, Vasic M, Vukicevic D, Zaric RZ, Kostic M. Measuring Patients' Knowledge About Adverse Effects of Angiotensin-Converting Enzyme Inhibitors. <i>J Patient Saf</i> 2016 doi: 10.1097/PTS.0000000000000244		
5.	Milovanović JR, Janković SM, Pejić A, Milosavljević M, Opančina V, Radonjić V, Protrka Z, Kostić M. Evaluation of brivaracetam: a new drug to treat epilepsy. <i>Expert Opin Pharmacother</i> 2017; 18(13):1381-1389.		
6.	Kostić M, Djaković L, Šujić R, Godman B, Janković SM. Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. <i>Appl Health Econ Health Policy</i> 2017;15(1):85-93.		
7.	Guzvic V, Catic T, Kostic M. Health Technology Assessment in Central-Eastern and South Europe Countries: Bosnia and Herzegovina. <i>Int J Technol Assess Health Care</i> . 2017;33(3):390-395.		
8.	Dabanović V, Kostić M, Janković S. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia—The Markov model based on data from Montenegro. <i>Vojnosanit Pregl</i> 2016; 73(1):26-33		
9.	Jankovic SM, Stojadinovic D, Stojadinovic M, Jankovic SV, Djuric JM, Stojic I, Kostic M. Angiotensin Receptor Blocker Losartan Inhibits Spontaneous Motility of Isolated Human Ureter. <i>Eur J Drug Metab Pharmacokinet</i> 2016;41(6):835-838.		
10.	Djokovic J, Milovanovic B, Milovanovic JR, Milovanovic O, Stojic I, Mrvic S, Kostic M, Stefanovic S, Jankovic SM. Translation of the Medical Fear Survey to Serbian: psychometric properties. <i>Hippokratia</i> 2016; 20 (1):44-9.		
11.	Sazdanovic P, Jankovic SM, Kostic M, Dimitrijevic A, Stefanovic S. Pharmacokinetics of linezolid in critically ill patients. <i>Expert Opin Drug Metab Toxicol</i> 2016;12(6):595-600.		
12.	Janković SM, Kostić M. Cost-Effectiveness of Introducing Point-of-Care Test for Detection of Level of Glycogen Phosphorylase in Early Diagnostic Algorithm of Acute Coronary Syndrome. <i>Value Health Reg Issues</i> . 2016;10:79-84.		
13.	Tesić D, Kostić M, Paunović D, Janković SM. Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia. <i>Kardiol Pol</i> . 2015;73(4):287-95.		
14.	MT. Tomovic, SM. Cupara, MT. Popovic-Milenkovic, BT. Ljubic, MJ. Kostic, SM. Jankovic. Antioxidant and anti-inflammatory activity of <i>Potentilla reptans</i> L. <i>Acta Poloniae Pharmaceutica - Drug Research</i> 2015; 72(1):137-145.		
15.	Kostić M, Jovanović S, Tomović M, Popović Milenković M, Janković SM. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from a Balkan country in socio-economic transition. <i>Vojnosanit Pregl</i> 2014; 71(2): 144-148.		
16.	Djordjevic N, Bogojevic J, and Kostic M. Alcohol consumption among adolescents in Kraljevo, Serbia. <i>Cent Eur J Med</i> 2011; 6(3): 363-371		
17.	Jankovic SM, Kostic M, Radosavljevic M, Tesic D, Stefanovic-Stoimenov N, Stevanovic I, Rakovic S, Aleksic J, Folic M, Aleksic A, Mihajlovic I, Biorac N, Borlja J, and Vuckovic R. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data from a Balkan country in socio-economic transition. <i>Vojnosanit Pregl</i> 2009; 66(7):556-562		
18.	Jankovic SM, Aleksic J, Rakovic S, Aleksic A, Stevanovic I, Stefanovic-Stoimenov N, Radosavljevic M, Kostic M, Tesic D, Petrovic B. Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. <i>J Nephrol</i> 2009; 22(4):502-507.		
19.	Jankovic SM, Kostic M, Radosavljevic M, Jovanovic S. Costs of Rheumatoid Arthritis in a Balkan Country (Serbia). <i>E Eur Polit Soc</i> 2009; 23(1):135-138		
20.	Kostić M. Rheumatoid arthritis: a novel approach in diagnosis and treatment. <i>Serb J Exp Clin Res</i> . 2018. doi: 10.1515/sjecr-2016-0068.		
21.	Kostić M. Cost effectiveness analysis of etanercept in combination with methotrexate for rheumatoid arthritis – Markov model based on data from Serbia. <i>Serb J Exp Clin Res</i> . 2017;18(4):343-7.		
22.	Praznik I, Spasić M, Radosavljević I, Stojanović B, Čanović D, Radovanović D, Savović Z, Vojinović R, Babić Ž, Đonović N, Luković T, Lazarević P, Đorđević N, Kostić I, Jelić I, Petrović J, Stojanović S, Jurišević M, Grubor I, Nikolić Lj, Vučićević K, Artinović V, Milojević A, Kostić M, Stefanović S, Janković S. Analysis of Treatment-Related Factors Affecting Mortality in Patients with Severe Necrotizing Acute Pancreatitis. <i>Acta Facultatis medicae Naissensis</i> . 2016;33(3):173–185.		
23.	Marković V, Kostić M, Iličković I, Janković SM. Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of <i>Clostridium difficile</i> Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition. <i>Value Health Reg Issues</i> . 2014;4:87-94.		
Збирни подаци научне, односно уметничке и стручне активности наставника			
Укупан број цитата	Science Citation Index, Web of Science		
	Scopus		
Укупан број радова са SCI или (SSCI) листе	19		
Тренутно учешће на пројектима	1	Домаћи	1
		Међународни	

Усавршавања	
Други релевантни подаци	Чланство: ISPOR